Statements (71)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
none reported
|
| gptkbp:budget |
available online
|
| gptkbp:businessModel |
ongoing
achievable biopharmaceutical development |
| gptkbp:CEO |
Pete_Salzmann
|
| gptkbp:clinicalTrials |
gptkb:United_States
diverse ongoing positive Phase 2 under development multiple states analyzed innovative favorable reported promising Phase 1, Phase 2, Phase 3 regularly provided Phase 1, Phase 2 IMVT-1401 Phase 1, Phase 2, Phase 3, Phase 4 |
| gptkbp:collaborations |
academic institutions
|
| gptkbp:communityEngagement |
active
|
| gptkbp:communityOutreach |
active
|
| gptkbp:communityPartnerships |
strategic
|
| gptkbp:employees |
approximately 100
|
| gptkbp:financialPerformance |
monitored
volatile |
| gptkbp:financials |
quarterly
publicly traded |
| gptkbp:focus |
autoimmune diseases
|
| gptkbp:focusArea |
IgG4-related diseases
|
| gptkbp:founded |
2018
|
| gptkbp:founder |
multiple individuals
|
| gptkbp:hasPrograms |
established
|
| gptkbp:hasResearchInterest |
conducted
|
| gptkbp:headquarters |
gptkb:New_York_City
|
| gptkbp:historicalResearch |
ongoing
|
| https://www.w3.org/2000/01/rdf-schema#label |
Immunovant, Inc.
|
| gptkbp:investmentFocus |
active
venture capital institutional investors regularly held |
| gptkbp:leadership |
experienced
|
| gptkbp:leads |
IMVT-1401
|
| gptkbp:market |
global
approximately $1 billion |
| gptkbp:marketingStrategy |
focus on autoimmune diseases
|
| gptkbp:partnerships |
various pharmaceutical companies
biotech companies |
| gptkbp:patentCitation |
filed
|
| gptkbp:portfolioCompany |
dedicated
|
| gptkbp:publicAccess |
completed in 2020
|
| gptkbp:regulatoryCompliance |
active
FDA_approval_pending |
| gptkbp:research |
secured
|
| gptkbp:research_areas |
immunology
|
| gptkbp:researchAndDevelopment |
innovative therapies
|
| gptkbp:researchFocus |
monoclonal antibodies
|
| gptkbp:researchInterest |
ongoing
published |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
IMVT
|
| gptkbp:strategicGoals |
expand pipeline
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:tributaryOf |
multiple candidates
|
| gptkbp:updates |
frequent
|
| gptkbp:website |
www.immunovant.com
|